Sexually Transmitted Disease (STD) Self-Testing Market Report 2025

The sexually transmitted disease (STD) self-testing market size has grown rapidly in recent years. It will grow from $1.38 billion in 2024 to $1.52 billion in 2025 at a compound annual growth rate (CAGR) of 10.1%. The growth during the historical period can be linked to greater awareness of sexual health, increased adoption of home-based healthcare options, the expansion of government-supported STD screening programs, wider accessibility of over-the-counter self-testing kits, and growing concerns over privacy associated with clinic-based testing.

The sexually transmitted disease (STD) self-testing market size is expected to see strong growth in the next few years. It will grow to $2.21 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The anticipated growth in the forecast period can be attributed to the rising prevalence of sexually transmitted infections, increasing preference for private and convenient testing methods, greater integration of digital health features in self-testing kits, broader availability of at-home diagnostics in developing regions, and growing regulatory approval of advanced self-testing technologies. Key trends expected during this period include progress in rapid molecular diagnostic tools, enhanced mobile app integration for tracking results, the creation of self-test kits that detect multiple infections, innovations in discreet packaging and delivery solutions, and advancements in AI-driven analysis of test outcomes.

The increasing number of syphilis cases is contributing to the growth of the sexually transmitted disease (STD) self-testing market. Syphilis is a sexually transmitted infection that causes sores and can result in severe health complications if untreated. The rise in syphilis infections is largely attributed to a decline in consistent condom use, especially among individuals involved in high-risk sexual behavior. STD self-testing offers a private and convenient method for individuals to screen themselves at home, encouraging early diagnosis. Early detection leads to timely treatment, reducing the risk of complications and helping prevent the spread of infection. For example, according to the Centers for Disease Control and Prevention (CDC), approximately 209,253 syphilis cases were reported in the United States in 2023, a 1% increase from the 207,269 cases reported in 2022. This growing prevalence is boosting the demand for self-testing solutions.

Companies in the STD self-testing market are developing innovative products like over-the-counter (OTC) sample collection kits to support early diagnosis and treatment. These OTC kits allow individuals to collect samples such as urine or swabs at home without a prescription, offering a discreet and user-friendly way to identify infections. In August 2023, iHealth Labs Inc., a US-based digital health company, introduced the CheckMeSafe home collection kit for HIV and syphilis testing. This FDA-approved kit enables individuals aged 18 and older to collect blood samples from home for testing HIV (types I, II, P24 antigen) and syphilis. Samples can be mailed to a laboratory using a prepaid overnight shipping label, with confidential results available in as little as two days. The kit delivers highly accurate outcomes, with sensitivity levels of up to 99.9% for HIV and 99.5% for syphilis. All tests are processed in a CLIA-certified and CAP-accredited lab, ensuring they meet federal and state quality regulations.

In December 2024, OraSure Technologies Inc., a US-based company that offers point-of-need and home diagnostic tests, acquired Sherlock Biosciences for an undisclosed amount. This acquisition is intended to expand OraSure’s presence in the at-home diagnostics market by incorporating Sherlock Biosciences’ CRISPR-based molecular technology. The integration of this advanced technology aims to create rapid, over-the-counter self-tests for STDs such as chlamydia and gonorrhea. These tests are designed to provide lab-quality results at home within minutes, making accurate and private STD testing more accessible. Sherlock Biosciences is a US-based company engaged in clinical trials for rapid OTC diagnostics for sexually transmitted infections.

Major players in the sexually transmitted disease (std) self-testing market are Abbott Laboratories, Viatris Inc., Hologic Inc., OraSure Technologies Inc., LifeCell International, LetsGetChecked Health Inc., Visby Medical Inc., Everlywell Inc., Guangzhou Wondfo Biotech Co. Ltd., NOWDiagnostics Inc., bioLytical Laboratories Inc., Atomo Diagnostics Limited, myLAB Box Inc., BioSure UK Ltd., JAL Medical (S) Pte Ltd., TBD Health Inc., Recombigen Laboratories Private Limited, Alpine Biomedicals Pvt. Ltd., Homed-IQ B.V., Newfoundland Diagnostics Pvt. Ltd.

North America was the largest region in the sexually transmitted disease (STD) self-testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in sexually transmitted disease (STD) self-testing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the sexually transmitted disease (STD) self-testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The sexually transmitted disease (STD) self-testing market consists of revenues earned by entities by providing services such as telehealth consultations, digital result delivery, follow-up care coordination, and online pre-test counselling. The market value includes the value of related goods sold by the service provider or included within the service offering. The sexually transmitted disease (STD) self-testing market includes sales of sample collection devices, buffer solutions or reagents, at-home diagnostic kits, mobile app-based test tracking tools, and smartphone-compatible test devices. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The sexually transmitted disease (STD) self-testing market research report is one of a series of new reports that provides sexually transmitted disease (STD) self-testing market statistics, including the sexually transmitted disease (STD) self-testing industry global market size, regional shares, competitors with the sexually transmitted disease (STD) self-testing market share, detailed sexually transmitted disease (STD) self-testing market segments, market trends, opportunities, and any further data you may need to thrive in the sexually transmitted disease (STD) self-testing industry. This sexually transmitted disease (STD) self-testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Sexually transmitted disease (STD) self-testing involves individuals collecting their own samples to screen for STDs without visiting a clinical facility. This approach offers a private, convenient, and prompt way to detect infections such as chlamydia, gonorrhea, HIV, and syphilis through at-home kits or mail-in laboratory services.

The primary types of STD self-testing samples include blood-based, urine-based, and oral-based tests. Blood-based self-tests typically use a small blood sample from a finger prick to effectively identify infections like HIV, syphilis, and hepatitis in their early stages. These tests are distributed through various channels, including hospital pharmacies, online pharmacies, and retail pharmacies, and are used for multiple purposes such as chlamydia trachomatis (CT) or Neisseria gonorrhoeae (NG) detection, syphilis screening, HIV testing, and more.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.